1. No Association of Plasma Prothrombin Concentration or the G20210A Mutation with Incident Cardiovascular Disease
- Author
-
Adam M. Smiles, Alice M. Arnold, Russell P. Tracy, Zhonghua Tang, Nancy S. Jenny, and Mary Cushman
- Subjects
education.field_of_study ,medicine.medical_specialty ,Pathology ,Vascular disease ,business.industry ,Population ,Prothrombin level ,Hematology ,medicine.disease ,Gastroenterology ,Diabetes mellitus ,Internal medicine ,Nested case-control study ,medicine ,cardiovascular diseases ,Risk factor ,education ,business ,Stroke ,Subclinical infection - Abstract
SummaryProthrombin is a key factor in blood clotting, a process intimately involved in thrombotic disease. We assessed prothrombin levels and G20210A genotype in a case-control study within the Cardiovascular Health Study. Cases included angina, myocardial infarction, stroke, and the presence of MRI-detectable infarcts (n ≈ 250 each). Populationbased controls free of clinical cardiovascular disease (CVD) (n ≈ 500) and a subset free of clinical and subclinical CVD (n ≈ 250) were used for comparison. The 20210 A allele, frequency 2.9%, was associated with higher mean prothrombin levels: 166.3 vs. 139.5 µg/ml (P
- Published
- 2002
- Full Text
- View/download PDF